Back to Interventions
Substance / Medication

Spinosad

SNOMED 725677000UMLS C0961781

Overview

Active Ingredient
spinosad
RxNorm CUI
299081
Labeler: Allegis Pharmaceuticals, LLCUpdated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Infestation by Pediculus
Infestation by Anoplura
Louse infestation

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Recent Trials

PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies

NCT05310734Phase 4Recruiting50 enrolled

Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation

NCT01660321Phase 4Completed26 enrolled
View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Speed of flea knockdown of spinosad compared to afoxolaner, and of spinosad through 28 days post-treatment in controlled laboratory studies.
Snyder Daniel E, Rumschlag Anthony J, Young Lisa Marie et al. · Parasit Vectors · 2015
PMID: 26552479RCTFull text (PMC)
A field trial of spinosad for the treatment and prevention of flea infestation in shepherd dogs living in close proximity to flea-infested sheep.
Saridomichelakis Manolis N, Chatzis Manolis K, Petanides Theodoros et al. · Parasit Vectors · 2015
PMID: 26065677RCTFull text (PMC)
Assessment of the combination of spinosad and milbemycin oxime in preventing the development of canine Angiostrongylus vasorum infections.
Böhm Claudia, Schnyder Manuela, Thamsborg Stig Milan et al. · Vet Parasitol · 2014
PMID: 24269160RCT
Efficacy of milbemycin oxime in combination with spinosad in the treatment of larval and immature adult stages of Ancylostoma caninum and Toxocara canis in experimentally infected dogs.
Bowman Dwight D, Reinemeyer Craig R, Wiseman Scott et al. · Vet Parasitol · 2014
PMID: 25108851RCT
Speed of kill efficacy and efficacy of flavored spinosad tablets administered orally to cats in a simulated home environment for the treatment and prevention of cat flea (Ctenocephalides felis) infestations.
Snyder Daniel E, Meyer Katherine A, Wiseman Scott et al. · Vet Parasitol · 2013
PMID: 23522900RCT
Safety and efficacy of spinosad chewable tablets for treatment of flea infestations of cats.
Paarlberg Tandy E, Wiseman Scott, Trout Candace M et al. · J Am Vet Med Assoc · 2013
PMID: 23547672RCT
Evaluation of the efficacy of topically administered imidacloprid + pyriproxyfen and orally administered spinosad against cat fleas (Ctenocephalides felis): Impact of treated dogs on flea life stages in a simulated home environment.
Ross Douglas H, Arther Robert G, von Simson Cristiano et al. · Parasit Vectors · 2012
PMID: 22958307RCTFull text (PMC)
Comparative efficacy on dogs of a single topical treatment with the pioneer fipronil/(S)-methoprene and an oral treatment with spinosad against Ctenocephalides felis.
Beugnet F, Doyle V, Murray M et al. · Parasite · 2011
PMID: 22091463RCTFull text (PMC)
Assessment of the effectiveness of a combination product of spinosad and milbemycin oxime on the prophylaxis of canine heartworm infection.
Snyder Daniel E, Wiseman Scott, Bowman Dwight D et al. · Vet Parasitol · 2011
PMID: 21530085RCT
Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation.
Sherman Jeffrey G, Paul Allan J, Firkins Lawrence D · Am J Vet Res · 2010
PMID: 20043790RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Spinosad (substance)
SNOMED CT
725677000
UMLS CUI
C0961781
RxNorm CUI
299081
Labeler
Allegis Pharmaceuticals, LLC

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.